KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBT (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed EBT for 9 consecutive years, with $248.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 1054.24% year-over-year to $248.0 million, compared with a TTM value of $267.4 million through Dec 2025, up 407.51%, and an annual FY2025 reading of $267.4 million, up 407.51% over the prior year.
  • EBT was $248.0 million for Q4 2025 at Biocryst Pharmaceuticals, up from $12.1 million in the prior quarter.
  • Across five years, EBT topped out at $248.0 million in Q4 2025 and bottomed at -$170.4 million in Q4 2023.
  • Average EBT over 3 years is $1.1 million, with a median of -$12.5 million recorded in 2024.
  • The sharpest move saw EBT soared 84.75% in 2024, then soared 1054.24% in 2025.
  • Year by year, EBT stood at -$170.4 million in 2023, then skyrocketed by 84.75% to -$26.0 million in 2024, then skyrocketed by 1054.24% to $248.0 million in 2025.
  • Business Quant data shows EBT for BCRX at $248.0 million in Q4 2025, $12.1 million in Q3 2025, and $6.5 million in Q2 2025.